The company states: “Silo Pharma (SILO) announced promising results from a preclinical study on SPC-15. This new formulation, which targets both the serotonin 5-HT4 receptor, 5-HT4R, and the NMDA receptor, NMDAR, has shown potential as a treatment for major depressive disorder, MDD, and other severe stress-related conditions. The study highlights the proposed efficacy of combining SPC-15, a 5-HT4R agonist, with an NMDAR antagonist to treat stress-induced behaviors. Results from animal models indicate that this dual-target approach may offer additional efficacy in treating severe conditions compared to using either agent alone, suggesting a potential enhanced therapeutic effect for managing severe psychiatric conditions. By simultaneously targeting 5-HT4R and NMDAR, the combined treatment demonstrated significant improvement in behavioral outcomes related to severe stress-induced conditions as compared to using either agent alone. The combination therapy showed a marked reduction in stress behaviors in animal models, indicating potential benefits for patients suffering from treatment-resistant depression. Eric Weisblum, CEO of Silo Pharma, stated: ‘In our opinion, our dual-action strategy with SPC-15 demonstrates the potential to provide an effective treatment option for patients experiencing severe and relapsed stress-related disorders.’ “
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SILO:
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
